Randomized Trialhigh evidence
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England journal of medicine·August 14, 2025·PMID 40544432
Why it mattersFor clinicians managing obesity with type 2 diabetes, this trial shows that dual amylin/GLP-1 therapy can deliver clinically meaningful additional weight loss and better glycemic control beyond lifestyle intervention alone, with a tolerability profile dominated by gastrointestinal effects.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled